What is the 13F Pro Quality Score for BVS?

13F Pro ranks Bioventus Inc. (BVS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View BVS's current score at https://13fpro.ai/research/BVS (free sign-up required for the full ranking).

Where does 13F Pro source BVS data?

All Bioventus Inc. fundamentals and ownership data come directly from SEC EDGAR. Bioventus Inc. files with the SEC under CIK 1665988. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is BVS in?

Bioventus Inc. (BVS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is BVS research updated on 13F Pro?

BVS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Bioventus Inc.(BVS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1665988 BVS stock profile & AI dashboard →

13F Pro Quality Score

50.0/100

Rank #1,483 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

45.5/100

Profitability

60.6/100

Balance Sheet

48.8/100

Earnings Quality

30.0/100

Free Cash Flow

58.6/100

Institutional Flow

68.6/100

Revenue Scale

38.1/100

Dilution Risk

39.4/100

BVS Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Bioventus Inc. (BVS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BVS at 50.0/100 on a 32-signal composite quality model, placing it at rank #1,483 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include earnings quality (30.0) and revenue scale (38.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 39.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Bioventus Inc. reports quarterly revenue of $132.1M, net income of $3.1M, an operating margin of 6.4%. Top institutional holders of BVS by reported 13-F value include Essex Woodlands Management,, Juniper Investment Company,, Nantahala Capital Management,, based on the most recent SEC filings. BVS trades on the Nasdaq exchange and files with the SEC under CIK 1665988. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BVS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Bioventus Inc. directly from SEC EDGAR. Bioventus Inc.'s 13F Pro composite quality score has ranged between 8 and 50 since 2022, currently 50.0 — a stable long-term trajectory across 52 quarterly and live scoring snapshots.

✦

Fun facts about Bioventus Inc.

Quirks, history, and lore behind BVS — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · small-cap · listed on Nasdaq · headquartered in North Carolina.
2
The Numbers
Annual revenue in the range of $500 million, with a product portfolio spanning dozens of SKUs sold largely through physicians, orthopedic surgeons, and outpatient clinics.
3
The History
The company went public in 2021, carving itself out of a larger medical-device parent to stand alone as a specialist in non-surgical, biological treatments for musculoskeletal conditions.
4
The Secret
Its core belief: skip the operating room. It sells products designed to help the body heal bone, joint, and soft tissue without a surgeon's scalpel — think bone grafts, hyaluronic acid injections, and platelet-rich plasma.
5
The Lore
The name itself is a mashup of biology and venture — fitting for a company that bets on the body's own healing pathways rather than implants or drugs.
6
The Giveaway
Ticker BVS, Durham-based, laser-focused on musculoskeletal healing without surgery — this is the company that wants your creaky knee fixed with biology, not a blade.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$132.1M

Net Income

Q1 2026

$3.1M

Free Cash Flow

Q1 2026

$8.4M

Operating Margin

Q1 2026

6.4%

ROIC

Q1 2026

1.9%

D/E Ratio

Q1 2026

1.44

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-0.9% YoY

$568.1MFY 2025

FY21 $430.9MFY22 $512.1MFY24 $573.3MFY25 $568.1M

Net Income

+162.9% YoY

$22.7MFY 2025

FY21 $19.4MFY22 $-158.7MFY24 $-36.1MFY25 $22.7M

Operating Income

+455.2% YoY

$54.0MFY 2025

FY21 $12.1MFY22 $-167.2MFY24 $-15.2MFY25 $54.0M

EPS (Diluted)

+158.9% YoY

$0.33FY 2025

FY21 $-0.15FY22 $-2.59FY24 $-0.56FY25 $0.33

Total Assets

-6.1% YoY

$683.6MFY 2025

FY21 $1.23BFY22 $1.37BFY24 $728.0MFY25 $683.6M

Total Debt

-12.4% YoY

$294.0MFY 2025

FY21 $375.7MFY22 $418.1MFY24 $335.6MFY25 $294.0M

Op. Cash Flow

+92.5% YoY

$74.7MFY 2025

FY21 $23.0MFY22 $-13.5MFY24 $38.8MFY25 $74.7M

Metric	FY 2025	FY 2024	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$568.1M -0.9%	$573.3M +11.9%	$512.1M +18.8%	$430.9M +34.2%	$321.2M -5.6%	$340.1M
Net Income	$22.7M +162.9%	$-36.1M +77.2%	$-158.7M -919.1%	$19.4M +18.1%	$16.4M +139.5%	$6.9M
Operating Income	$54.0M +455.2%	$-15.2M +90.9%	$-167.2M -1486.6%	$12.1M -43.2%	$21.2M -31.9%	$31.2M
EPS (Diluted)	$0.33 +158.9%	$-0.56 +78.4%	$-2.59 -1626.7%	$-0.15	—	—
Total Assets	$683.6M -6.1%	$728.0M -47.0%	$1.37B +12.0%	$1.23B +147.9%	$494.5M	—
Total Debt	$294.0M -12.4%	$335.6M -19.7%	$418.1M +11.3%	$375.7M +99.5%	$188.4M	—
Operating Cash Flow	$74.7M +92.5%	$38.8M +386.6%	$-13.5M -158.9%	$23.0M -68.0%	$71.8M +76.4%	$40.7M

AI Insight: BVS Financial Trends

Bioventus has turned the corner: net income positive for four consecutive quarters while total debt fell $112M from peak to Q1 2026.

• Net income swung from -$26M in Q2 2024 to +$15M in Q4 2025, marking four straight quarters of profitability through Q1 2026.

• Total debt declined from $384M in Q3 2024 to $272M in Q1 2026, a $112M reduction over five quarters.

• Operating cash flow improved sharply from -$19M in Q1 2025 to $38M in Q4 2025, though it pulled back to $9M in Q1 2026.

• Equity grew from $148M in Q1 2025 to $189M in Q1 2026, reflecting accumulated earnings strengthening the balance sheet.

⚠ Q1 2026 operating cash flow dropped to $9M from $38M in Q4 2025 — monitor whether this is seasonal or a trend reversal.

⚠ Revenue of $132M in Q1 2026 is flat vs. $124M in Q1 2025, suggesting limited top-line growth momentum.

⚠ Total debt remains elevated at $272M against equity of $189M; leverage ratio still warrants close monitoring.

AI Insight: BVS Ratio Trends

Bioventus has crossed into sustained profitability after a deep Q2 2024 loss, with D/E compressing from 2.58 to 1.44 over five quarters.

• Operating margin swung from -21.1% in Q2 2024 to a TTM of 10.0%, marking a full profitability recovery.

• D/E ratio declined steadily from 2.58 in Q3 2024 to 1.44 in Q1 2026, signaling consistent deleveraging.

• ROIC turned positive by Q3 2024 and reached 16.3% in Q4 2025, though Q1 2026 pulled back to 7.3%.

• Net profit margin turned positive in Q2 2025 at 5.1% and peaked at 9.3% in Q4 2025 before easing to 2.4% in Q1 2026.

⚠ Q1 2026 shows sequential deterioration: OpMargin fell from 12.3% to 6.4% and ROIC from 16.3% to 7.3% — watch for seasonality vs. structural softness.

⚠ D/E at 1.44 remains elevated; continued deleveraging pace warrants monitoring given still-thin quarterly margins.

⚠ ROE swings are extreme quarter-to-quarter (32.1% in Q4 2025 vs. 6.6% in Q1 2026), suggesting earnings quality and consistency need confirmation.

Get alerted when BVS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Bioventus Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of BVS

Essex Woodlands Management, Inc.
$118.9M13,021,324 sh
Juniper Investment Company, LLC
$63.4M6,939,357 sh
Nantahala Capital Management, LLC
$55.9M6,122,403 sh
BlackRock, Inc.
$28.6M3,133,541 sh
VANGUARD CAPITAL MANAGEMENT LLC
$15.7M1,714,707 sh
ROYCE & ASSOCIATES LP
$14.1M1,541,282 sh
GEODE CAPITAL MANAGEMENT, LLC
$10.7M1,168,247 sh
STATE STREET CORP
$9.0M988,367 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$8.9M973,004 sh
DIMENSIONAL FUND ADVISORS LP
$8.0M873,138 sh

Fund	Value	Shares
Essex Woodlands Management, Inc.	$118.9M	13,021,324
Juniper Investment Company, LLC	$63.4M	6,939,357
Nantahala Capital Management, LLC	$55.9M	6,122,403
BlackRock, Inc.	$28.6M	3,133,541
VANGUARD CAPITAL MANAGEMENT LLC	$15.7M	1,714,707
ROYCE & ASSOCIATES LP	$14.1M	1,541,282
GEODE CAPITAL MANAGEMENT, LLC	$10.7M	1,168,247
STATE STREET CORP	$9.0M	988,367
VANGUARD PORTFOLIO MANAGEMENT LLC	$8.9M	973,004
DIMENSIONAL FUND ADVISORS LP	$8.0M	873,138

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put BVS on your watchlist

Track score changes the day Bioventus Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is BVS a good stock to buy?

13F Pro's AI-powered analysis of Bioventus Inc. (BVS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BVS are available on the BVS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own BVS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BVS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Bioventus Inc.'s investment landscape.